Celsion Corporation News Releases http://investor.celsion.com/ Celsion Corporation News Releases en Celsion Corporation Reports First Quarter 2019 Financial Results and Provides Business Update http://investor.celsion.com/news-releases/news-release-details/celsion-corporation-reports-first-quarter-2019-financial-results Company to Hold Conference Call on Wednesday, May 15, 2019 at 11:00 a.m. EDT LAWRENCEVILLE, N.J , May 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2019 and provided an update Wed, 15 May 2019 08:00:00 -0400 Celsion Corporation News Releases 17601 Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019 http://investor.celsion.com/news-releases/news-release-details/celsion-corporation-hold-first-quarter-2019-financial-results-0 LAWRENCEVILLE, N.J. , May 08, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2019 and provide an update on its development programs for ThermoDox ® , its Wed, 08 May 2019 17:00:00 -0400 Celsion Corporation News Releases 17596 Celsion Corporation Announces Issuance of New Patent for ThermoDox® http://investor.celsion.com/news-releases/news-release-details/celsion-corporation-announces-issuance-new-patent-thermodoxr   Represents a Significant Advance for Celsion’s Life Cycle Management Program for ThermoDox ®           Establishing Bioequivalence Will Extend Market Exclusivity to 2033 LAWRENCEVILLE, N.J , April 17, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical stage oncology drug Wed, 17 Apr 2019 08:00:00 -0400 Celsion Corporation News Releases 17581 Celsion Corporation to Participate in Two Investor Conferences in May 2019 http://investor.celsion.com/news-releases/news-release-details/celsion-corporation-participate-two-investor-conferences-may    Company to Discuss its Ongoing Pivotal Phase III Study in Primary Liver Cancer and  its Phase I/II Clinical Study in Ovarian Cancer LAWRENCEVILLE, N.J. , April 12, 2019 (GLOBE NEWSWIRE) --   Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Fri, 12 Apr 2019 08:30:00 -0400 Celsion Corporation News Releases 17576 Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019 http://investor.celsion.com/news-releases/news-release-details/celsion-corporation-hold-first-quarter-2019-financial-results LAWRENCEVILLE, N.J. , April 12, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2019 and provide an update on its development programs for ThermoDox®, its Fri, 12 Apr 2019 08:00:00 -0400 Celsion Corporation News Releases 17566 Celsion Corporation Reports 2018 Financial Results http://investor.celsion.com/news-releases/news-release-details/celsion-corporation-reports-2018-financial-results Celsion Enters 2019 with a Strong Balance Sheet, Clean Capitalization Structure and an Advancing Clinical Pipeline  Company to Hold Conference Call on Friday, March 29, 2019 at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , March 29, 2019 (GLOBE NEWSWIRE) --   Celsion Corporation (NASDAQ: CLSN), an oncology Fri, 29 Mar 2019 08:00:00 -0400 Celsion Corporation News Releases 17531 Celsion Corporation to Hold Year-End 2018 Financial Results Conference Call on Friday, March 29, 2019 http://investor.celsion.com/news-releases/news-release-details/celsion-corporation-hold-year-end-2018-financial-results LAWRENCEVILLE, N.J , March 22, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended December 31, 2018 and provide an update on its development programs for ThermoDox®, its proprietary Fri, 22 Mar 2019 08:30:00 -0400 Celsion Corporation News Releases 17516 Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium http://investor.celsion.com/news-releases/news-release-details/celsion-announces-gen-1-data-presentation-asco-sitc-clinical 100% Objective Response Rates and 88% Complete (R0) Resection Rates in Highest Dose Cohorts GEN-1 Intraperitoneally Delivered Durable Local Levels of Pro-Immune IL-12 and Related Cytokines Dose Dependent Reduction in Immunosuppressive Biomarkers Suggest Positive Effect on Tumor Microenvironment Mon, 04 Mar 2019 08:30:00 -0500 Celsion Corporation News Releases 17481 Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) http://investor.celsion.com/news-releases/news-release-details/celsion-corporation-reports-inducement-grants-under-nasdaq-0 LAWRENCEVILLE, N.J. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on February 19, 2019 , the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the Thu, 21 Feb 2019 16:30:00 -0500 Celsion Corporation News Releases 17421 Celsion Corporation to Present at NobleConXV – Noble Capital Markets’ 15th Annual Investor Conference http://investor.celsion.com/news-releases/news-release-details/celsion-corporation-present-nobleconxv-noble-capital-markets LAWRENCEVILLE, N.J. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Jeffrey Church , Celsion’s Executive Vice President and Chief Financial Officer, will present at NobleConXV - Noble Capital Markets’ 15 th Annual Thu, 24 Jan 2019 11:30:00 -0500 Celsion Corporation News Releases 17416